News Feed
- Tuesday 18th June 2013
Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition.read more
- Monday 17th June 2013
AstraZeneca announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.read more
- Sunday 16th June 2013
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity.read more
- Friday 14th June 2013
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis.read more
- Wednesday 12th June 2013
Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk" launches of generic Protonix® in the United States.read more
- Tuesday 11th June 2013
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.read more
- Monday 10th June 2013
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine. Fluzone Quadrivalent vaccine is the newest addition to the Fluzone family of influenza vaccines.read more
- Monday 10th June 2013
AstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.read more
- Sunday 9th June 2013
The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published. Some independent studies challenge the conclusions of the drugs manufacturers' own research. Now some medical experts and patient groups are calling on the pharmaceutical companies to be more transparent in reporting of study data and to enter into dialogue about safety concerns.read more
- Thursday 6th June 2013
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers.read more
- Wednesday 5th June 2013
A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research. In MS, the immune system attacks and destroys myelin, the insulating layer that forms around nerves in the spinal cord, brain and optic nerve.read more
- Tuesday 4th June 2013
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted a Priority Review designation for the Biologics License Application (BLA) for metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD), a rare disease estimated to affect a few thousand people around the world, often with an early age of onset.read more
- Monday 3rd June 2013
Using cholesterol-lowering statins may be associated with musculoskeletal conditions, arthropathies (joint diseases) and injuries, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication. While statins effectively lower cardiovascular illnesses and death, the full spectrum of statin musculoskeletal adverse events (AEs) is unknown.read more
- Monday 3rd June 2013
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively.read more
- Sunday 2nd June 2013
MyHealthAvatar project aims to proof the concept of the digital representation of your health status. Your health status will be designed as a lifetime companion (Avatar). Your Health Avatar will facilitate the collection of, and access to, long-term health-status information. This will be extremely valuable for healthcare decisions and offer a promising approach to support health research.read more
- Thursday 30th May 2013
Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomised trial published and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.read more
- Wednesday 29th May 2013
Amgen (NASDAQ:AMGN), the world's largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas"), a leading Tokyo-based global pharmaceutical company, announced the companies have entered into a strategic alliance to provide new medicines to help address serious unmet medical needs of Japanese patients.read more
- Wednesday 29th May 2013
Today Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS. Novartis is committed to supporting the MS community through these initiatives, in addition to delivering and researching innovative treatments to help address the high unmet medical needs of people with MS at every stage of the disease.read more
- Tuesday 28th May 2013
AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.read more
- Monday 27th May 2013
Two mutations central to the development of infantile myofibromatosis (IM) - a disorder characterized by multiple tumors involving the skin, bone, and soft tissue - may provide new therapeutic targets, according to researchers from the Icahn School of Medicine at Mount Sinai. The findings, published in the American Journal of Human Genetics, may lead to new treatment options for this debilitating disease, for which the only current treatment option is repeated surgical removal of the tumors.read more
